Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Cellular therapy and induced neuronal replacement for Huntington's disease.

Benraiss A, Goldman SA.

Neurotherapeutics. 2011 Oct;8(4):577-90. doi: 10.1007/s13311-011-0075-8. Review.

2.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

3.

Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells.

Lorincz MT, Zawistowski VA.

Mol Cell Neurosci. 2009 Jan;40(1):1-13. doi: 10.1016/j.mcn.2008.06.004. Epub 2008 Jun 19.

4.

Reduction in subventricular zone-derived olfactory bulb neurogenesis in a rat model of Huntington's disease is accompanied by striatal invasion of neuroblasts.

Kandasamy M, Rosskopf M, Wagner K, Klein B, Couillard-Despres S, Reitsamer HA, Stephan M, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Hörsten S, Aigner L.

PLoS One. 2015 Feb 26;10(2):e0116069. doi: 10.1371/journal.pone.0116069. eCollection 2015.

5.

Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.

Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H.

Mol Brain. 2012 May 21;5:17. doi: 10.1186/1756-6606-5-17.

6.

Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB.

J Huntingtons Dis. 2015;4(1):17-36.

7.

Huntington's disease: new frontiers for molecular and cell therapy.

Melone MA, Jori FP, Peluso G.

Curr Drug Targets. 2005 Feb;6(1):43-56. Review.

PMID:
15720212
8.

Selective neuronal degeneration in Huntington's disease.

Cowan CM, Raymond LA.

Curr Top Dev Biol. 2006;75:25-71. Review.

PMID:
16984809
9.

Therapeutic Strategies for Huntington's Disease.

Mrzljak L, Munoz-Sanjuan I.

Curr Top Behav Neurosci. 2015;22:161-201. doi: 10.1007/7854_2013_250. Review.

PMID:
24277342
10.

Mitochondrial fragmentation in neuronal degeneration: Toward an understanding of HD striatal susceptibility.

Cherubini M, Ginés S.

Biochem Biophys Res Commun. 2017 Feb 19;483(4):1063-1068. doi: 10.1016/j.bbrc.2016.08.042. Epub 2016 Aug 8. Review.

PMID:
27514446
11.

[Huntington disease. A review].

Bonilla E.

Invest Clin. 2000 Jun;41(2):117-41. Review. Spanish.

PMID:
10961047
12.

HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.

Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME.

Hum Mol Genet. 2005 Oct 1;14(19):2871-80. Epub 2005 Aug 22.

PMID:
16115812
13.

Replicating Huntington's disease phenotype in experimental animals.

Brouillet E, Condé F, Beal MF, Hantraye P.

Prog Neurobiol. 1999 Dec;59(5):427-68. Review.

PMID:
10515664
14.

Foundation-directed therapeutic development in Huntington's disease.

Dominguez C, Munoz-Sanjuan I.

J Med Chem. 2014 Jul 10;57(13):5479-88. doi: 10.1021/jm4009295. Epub 2014 Feb 4.

PMID:
24432836
15.

The molecular biology of Huntington's disease.

Ho LW, Carmichael J, Swartz J, Wyttenbach A, Rankin J, Rubinsztein DC.

Psychol Med. 2001 Jan;31(1):3-14. Review.

PMID:
11200958
16.

Use of human stem cells in Huntington disease modeling and translational research.

Golas MM, Sander B.

Exp Neurol. 2016 Apr;278:76-90. doi: 10.1016/j.expneurol.2016.01.021. Epub 2016 Jan 27. Review.

PMID:
26826449
17.

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.

PMID:
19909260
18.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

19.

Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Ehrlich ME.

Neurotherapeutics. 2012 Apr;9(2):270-84. doi: 10.1007/s13311-012-0112-2. Review.

20.

Towards a transgenic model of Huntington's disease in a non-human primate.

Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW.

Nature. 2008 Jun 12;453(7197):921-4. doi: 10.1038/nature06975. Epub 2008 May 18.

Supplemental Content

Support Center